Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Amendment history:
  • Correction (February 1983)

Research Article Free access | 10.1172/JCI110746

Cyclosporin A-treated guinea pig responder cells secrete a genetically restricted factor that suppresses the mixed leukocyte reaction.

G A DosReis and E M Shevach

Find articles by DosReis, G. in: PubMed | Google Scholar

Find articles by Shevach, E. in: PubMed | Google Scholar

Published January 1, 1983 - More info

Published in Volume 71, Issue 1 on January 1, 1983
J Clin Invest. 1983;71(1):165–169. https://doi.org/10.1172/JCI110746.
© 1983 The American Society for Clinical Investigation
Published January 1, 1983 - Version history
View PDF
Abstract

Cyclosporin A (CY A) is a hydrophobic, undecapeptide, fungal metabolite with potent immunosuppressive effects on T lymphocyte-mediated immune responses. Suppressor T lymphocytes generated during a mixed leukocyte reaction (MLR) performed in the presence of CY A, release a factor that suppresses a primary MLR of responder T cells, which is derived from the same strain as the factor producer but lacks specificity for the stimulator cell. These results suggest a finely regulated pathway by which CY A may induce and maintain a permanent state of transplantation tolerance in vivo.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 165
page 165
icon of scanned page 166
page 166
icon of scanned page 167
page 167
icon of scanned page 168
page 168
icon of scanned page 169
page 169
Version history
  • Version 1 (January 1, 1983): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts